MRM
Medirom Healthcare Technologies Inc.
$1.18
0.00%
$9.3M
No data for this timeframe.
Vol
Market Cap$9.3M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$2.2K
Inst. Activity0 buys / 1 sells
SEC Reports3
Recent Activity
May 29, 2026
SEC
Medirom Healthcare Technologies disclosed receipt of a Nasdaq deficiency notice for failing to timely file its FY2025 Fo
6-K — Impact 7/10
May 28, 2026
SEC
MEDIROM reported Q1 2026 operational KPIs showing continued salon count decline (-21 salons YoY to 287) and a 13.9% drop
PRESS-RELEASE — Impact 4/10
May 28, 2026
earnings
MEDIROM Group Reports Q1 2026 Results
<p align="left" style="padding-left:0pt;">TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report pres
May 28, 2026
SEC
MEDIROM reported Q1 2026 KPIs showing a sharp 13.9% YoY decline in total salon customers (192k vs 223k) and a net closur
6-K — Impact 6/10
Inst.
RHUMBLINE ADVISERS — TRIM
1,984 shares ($2.2K)
Inst.
RHUMBLINE ADVISERS — DOUBLED
4,253 shares ($8.3K)
Latest Reports
BEARISH
6-K
7/10
Medirom Healthcare Technologies disclosed receipt of a Nasdaq deficiency notice for failing to timely file its FY2025 Fo
May 29, 2026
NEUTRAL
PRESS-RELEASE
4/10
MEDIROM reported Q1 2026 operational KPIs showing continued salon count decline (-21 salons YoY to 287) and a 13.9% drop
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RHUMBLINE ADVISERS | $2.2K | TRIM |
| HRT FINANCIAL LP | $13.00 | — |
2 institutional holders with $2.2K total value (13,889 shares) as of 2026-Q1. Top holders: RHUMBLINE, HRT. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RHUMBLINE ADVISERS | 1,984 | $2.2K | 99.4% | TRIM -53.4% |
| 2 | HRT FINANCIAL LP | 11,905 | $13.00 | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | TRIM | 4,253 | 1,984 | -53.4% | $2.2K | 2026-Q1 |
| RHUMBLINE ADVISERS | DOUBLED | 1,307 | 4,253 | +225.4% | $8.3K | 2025-Q4 |
| UBS Group AG | TRIM | 98,284 | 33,280 | -66.1% | $47.3K | 2025-Q2 |
| UBS Group AG | DOUBLED | 45,174 | 98,284 | +117.6% | $36.2K | 2025-Q1 |
| UBS Group AG | DOUBLED | 18,037 | 45,174 | +150.5% | $46.5K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BEARISH
6-K
7/10
Medirom Healthcare Technologies disclosed receipt of a Nasdaq deficiency notice for failing to timel
May 29, 2026
NEUTRAL
PRESS-RELEASE
4/10
MEDIROM reported Q1 2026 operational KPIs showing continued salon count decline (-21 salons YoY to 2
May 28, 2026
BEARISH
6-K
6/10
MEDIROM reported Q1 2026 KPIs showing a sharp 13.9% YoY decline in total salon customers (192k vs 22
May 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
$HIMX - CPO Microlens Supplier
▲ 1
💬 0
⚡ 0.5
May 28, 2026
earnings
MEDIROM Group Reports Q1 2026 Results
<p align="left" style="padding-left:0pt;">TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report presents an overview of our business performance and k
May 22, 2026
short_volume
Short Volume: MRM — 55.1% short (1.5M / 2.8M)
Short: 1,538,732 | Exempt: 32,595 | TRF Vol: 2,795,032 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)